Carcinoma of the cervix uteri: an assessment of the relationship of tumour proliferation to prognosis.
The aim of this study was to ascertain whether assessing the growth fraction of cervical carcinoma of 28 patients, using antibody Ki-67, would be of value in clinical practice. The results showed no relationship between growth fraction and age, clinical stage, lymph node involvement or short term (3-5 years) survival.
Cole
D J
DJ
Department of Radiotherapy and Oncology, Churchill Hospital, Oxford, UK.
Brown
D C
DC
Crossley
E
E
Alcock
C J
CJ
Gatter
K C
KC
D000230:Adenocarcinoma / Q000276:immunology / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000401:mortality / Q000473:pathology*; D002455:Cell Division / Q000502:physiology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen; D008875:Middle Aged; D009687:Nuclear Proteins / Q000032:analysis; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology*
D000911:Antibodies, Monoclonal; D019394:Ki-67 Antigen; D009687:Nuclear Proteins